Clinical Trial Update: Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention [Phase 4]

View source ↗

Summary

Phase 4 trial addressing concentration-effect relationship of enoxaparin for thromboembolic prevention has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Sars-CoV2 | Phase 4 | Status: WITHDRAWN